Open AccessChallenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy
Author(s) -
Allen Jeffrey A.,
Gorson Kenneth C.,
Gelinas Deborah
Publication year - 2018
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.932
Subject(s) - chronic inflammatory demyelinating polyneuropathy , medicine , polyradiculoneuropathy , specialty , polyneuropathy , pediatrics , physical therapy , antibody , pathology , guillain barre syndrome , immunology
We explored adherence to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) by reviewing data from a specialty pharmacy database. Materials and Methods Clinical and electrophysiologic data were reviewed for 65 consecutive patients treated with intravenous immunoglobulin (IVIG) for CIDP. Three neuromuscular neurologists independently classified cases according to EFNS/PNS criteria as (1) fulfilling CIDP criteria; (2) non‐CIDP (neither clinical nor electrophysiologic criteria met); or (3) unknown (insufficient information). Results Patients were treated by 31 different community neurologists in 14 states. Only seven patients (11%) met clinical and electrodiagnostic CIDP criteria. The remainder (89%) did not have CIDP (49%) or were unknown (40%). IVIG mean induction dose was 1.25 g/kg, mean maintenance dose 0.79 g/kg, and mean interval between infusions was 23 days. Conclusions Adherence to EFNS/PNS CIDP diagnostic and treatment guidelines in the general neurologic community was poor. Improved education and awareness of widely available CIDP guidelines are recommended.